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Abstract
Objective
Where human African trypanosomiasis (HAT) patients are seen, failure to microscopically
diagnose infections by Trypanosoma brucei gambiense in blood smears and/or cerebrospi-
nal fluid (CSF) in the critical early stages of the disease is the single most important factor in
treatment failure, a result of delayed treatment onset or its absence. We hypothesized that
the enhanced sensitivity of detergent-enhanced loop-mediated isothermal amplification
(LAMP) will allow for point of care (POC) detection of African trypanosomes in the CSF of
HAT patients where the probability for detecting a single parasite or parasite DNA molecule
in 1 μL of CSF sample is negligible by current methods.
Methodology
We used LAMP targeting the multicopy pan-T. brucei repetitive insertion mobile element
(RIME LAMP) and the Trypanosoma brucei gambiense 5.8S rRNA-internal transcribed
spacer 2 gene (TBG1 LAMP). We tested 1 μL out of 20 μL sham or Triton X-100 treated
CSFs from 73 stage-1 and 77 stage-2 HAT patients from the Central African Republic and
100 CSF negative controls.
Results
Under sham conditions, parasite DNA was detected by RIME and TBG1 LAMP in 1.4% of
the stage-1 and stage-2 gambiense HAT CSF samples tested. After sample incubation with
detergent, the number of LAMP parasite positive stage-2 CSF’s increased to 26%, a value
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which included the 2 of the 4 CSF samples where trypanosomes were identified microscopi-
cally. Unexpected was the 41% increase in parasite positive stage-1 CSF’s detected by
LAMP. Cohen’s kappa coefficients for RIME versus TBG1 LAMP of 0.92 (95%CI: 0.82–
1.00) for stage-1 and 0.90 (95%CI: 0.80–1.00) for stage-2 reflected a high level of agree-
ment between the data sets indicating that the results were not due to amplicon contamina-
tion, data confirmed in χ2 tests (p<0.001) and Fisher’s exact probability test (p = 4.7e-13).
Conclusion
This study detected genomic trypanosome DNA in the CSF independent of the HAT stage
and may be consistent with early CNS entry and other scenarios that identify critical knowl-
edge gaps for future studies. Detergent-enhanced LAMP could be applicable for non-inva-
sive African trypanosome detection in human skin and saliva or as an epidemiologic tool for
the determination of human (or animal) African trypanosome prevalence in areas where
chronically low parasitemias are present.
Author summary
Human African trypanosomiasis is a fatal disease (if untreated) spread by bloodsucking
tsetse flies. These protozoan parasites first enter the lymph and blood to invade many
organ systems (early stage sleeping sickness). Weeks to months later, the parasites invade
the brain causing a wide variety of neurological symptoms (late stage sleeping sickness).
In rural clinical settings, diagnosis still relies on the detection of these microbes in blood
and cerebrospinal fluid (CSF) by microscopy. LAMP, or loop-mediated isothermal ampli-
fication of DNA, is a technique that can specifically detect very small amounts of DNA
from an organism. We previously showed that by simply adding detergent during sample
preparation, the analytical sensitivity of LAMP targeting many gene copies is greatly
improved, presumably because DNA is released from the pathogen cells and dispersed
through the sample. We demonstrated proof of principle using pathogenic trypanosomes
in different human body fluids (CSF or blood) and showed that this simple modification
should be applicable for diagnosis of other microbial infections where cells are sensitive to
detergent lysis. After completion of the above published study, we tested a collection of
clinical CSF samples from African patients diagnosed with early or late stage sleeping sick-
ness based on current World Health Organization (WHO) guidelines. For proof-of-con-
cept we tested only a single microliter of detergent-treated CSF to test for late stage
disease. We predicted that a significant number of the late stage samples would be LAMP
positive, while the early stage CSFs would yield predominantly negative results. Instead,
our study detected trypanosome DNA in patient CSF independent of African sleeping
sickness stage, results that may be consistent with early brain entry and other scenarios
that identify critical knowledge gaps for future studies.
Introduction
In East Africa, the tsetse fly-transmitted protozoan parasite Trypanosoma brucei rhodesiense
causes acute human African trypanosomiasis (HAT/ sleeping sickness) [1]. Transmitted from
animals to man, T. b. rhodesiense infection is a zoonosis characterized by relatively high
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parasite loads. Over 97% of all HAT cases occur in West and Central Africa where the disease
is caused by T. b. gambiense, which causes chronic disease with intermittent parasitemias char-
acterized by low parasite numbers [2, 3]. In 2016, the number of patients with HAT reported
by the World Health Organization (WHO) was fewer than 2,000; however, with many unre-
ported cases, the estimate of actual number of infected people in the remaining endemic coun-
tries in Africa is probably higher [4]. History has shown that HAT reappears at epidemic cyclic
intervals as parasites from chronically infected individuals without clinical signs of disease or
harbored in animal reservoirs re-emerge back into the population [5–7].
The disease is marked by an early systemic hemolymphatic stage-1 phase, where the clinical
symptoms and signs are easily confused with those of other infectious diseases (i.e. malaria,
viral syndromes). Left untreated, the parasites invade the central nervous system (CNS; stage-
2), a process that usually takes weeks to months with T. b. rhodesiense or months to years for
T. b. gambiense infections. Both parasites cause white matter encephalitis (leukoencephalitis)
that belies neuropathologic manifestations that lead to death if untreated [reviewed in [8, 9]].
Night time insomnia and day time drowsiness, which give the disease its name, are the most
characteristic neurologic signs of gambiense HAT. However, the somnolence and other late
stage mental signs are less common in Rhodesian disease, although there may be mental slow-
ness or dullness and drowsiness or coma in terminal disease [10]. A key issue in the diagnosis
and treatment of HAT is to distinguish reliably CNS involvement with HAT from the early
stage disease. Accurate staging of HAT is critical because failure to treat a patient with CNS
involvement using stage-2 drugs will lead inevitably to death from the disease, yet inappropri-
ate CNS treatment in an early-stage patient carries a high risk of unnecessary drug toxicity and
potentially death.
The diagnosis and staging of HAT in the rural clinical setting where most patients are
found, is time consuming, difficult and still relies largely on the microscopic detection of para-
sites in clinical samples (blood smear, lymph, CSF). While this approach is inherently insensi-
tive, it is still considered the unofficial gold-standard for specific diagnosis [11–13]. Where the
disease is hyperendemic and since trypanosomes can be difficult to detect in CNS HAT, espe-
cially in the late stage [14], failure by these methods to correctly classify stage-2 from stage-1
disease is probably the single most important contributor to disease progression and treatment
failure [11]. While T. b. rhodesiense detection in blood is frequently successful, for T. b. gam-
biense infections, where only a few parasites are present in the peripheral circulation or in CSF,
a thorough search is required, but is time consuming and subjective. Concentration techniques
such as double centrifugation or mini-anion exchange columns (mAECT) are usually neces-
sary [11–13].
Because of the inherent difficulties associated in detection of parasites in gambiense HAT
patient CSF samples, examination of white cell count/protein concentrations suggestive of
chronic meningoencephalitis is required. Because CNS involvement is often-silent, staging
relies on lumbar puncture to assess chronic meningoencephalitis, especially in field screening
wherein few cases have neurological signs [14, 15]. CSF leukocyte counts are scored according
to stage-2 cut-offs recommended by WHO [12]. Detection of trypanosomes in CSF does not
define ‘chronic’ CNS infection, since the immune system may also destroy the parasite [14,
16]. Hence, determination of persistent disease to eliminate parasite reservoirs in the popula-
tion remains an unmet challenge.
Assay sensitivity for T. b. gambiense detection even by molecular tests, i.e. polymerase
chain reaction (PCR) and loop-mediated isothermal amplification (LAMP) [17–23], is often
limited by the stoichiometric presence of the parasite in the assayed sample. Cox et al. [24]
reported the difficulty to establish true trypanosome (T. congolense, T. vivax, T. b. brucei) prev-
alence in blood spotted on paper cards using specific PCR detection tools in indigenous
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African zebu cattle due to chronically low parasitemias [24]. Because parasite DNA was
unevenly distributed across the card, a single punch from an FTA card was insufficient to con-
firm infectivity: i,e. the stochastic sampling effect results in underestimation of prevalence
[24]. The same stoichiometric apply to blood/CSF-based molecular assays sufficiently sensitive
to detect DNA below the content of a single parasite; i.e. the detection limit of the assay is still
restricted by the number of parasites present in the volume of sample assayed [22].
Remarkably, the answer was simple: i.e. LAMP assays that recognize multi-copy gene tar-
gets for trypanosome DNA are dramatically enhanced by sample pretreatment with detergents
to lyse or solubilize their DNA prior to assay [22]. By pre-lysing cells with detergent before
application of parasite-specific LAMP primers and amplification that recognize multi-copy
gene targets we have been able to markedly improve the detection of parasite genomic DNA
by LAMP. Using human CSF spiked with trypanosomes as direct source of DNA template, we
found that detergent-enhanced LAMP assay targeting multi-copy trypanosome genes reached
analytical sensitivities about 100 to 1000-fold or lower [22]. Similar increases in LAMP assay
analytical sensitivity were also found using DNA extracted from filter paper cards containing
blood pretreated with detergent before card spotting, or using DNA extracted from blood sam-
ples spotted on detergent-pretreated air-dried cards for improved assay reproducibility [22].
Hayashida et al [25] later showed that RNA could also be amplified directly from detergent-
lysed blood samples.
Here we assess and show that detergent-enhanced LAMP is a simple point of care (POC)
molecular assay platform for T. b. gambiense parasite detection in clinical samples where
chronically low parasitemias are expected. As stage determination relies on lumbar puncture
to examine CSF for trypanosomes confirming neurological invasion [15], our findings are
intriguing in that the data provide evidence for detection of genomic T. b. gambiense DNA in
the CSF independent of HAT stage. Overall, it is predicted that this simple technological
advance will greatly improve POC pathogen detection including those trypanosomes in the
so-called aparasitemic individuals who also may or may not be seropositive for the parasites
and environmental monitoring.
Materials and methods
The clinical samples and ethical statement
A de-identified cohort of 150 clinical samples was obtained from HAT patients during studies
in Central African Republic (Batangafo focus, 2001) under the direction of “Programme
National de Lutte contre la Trypanosomose Humaine Africaine” (PNLTHA) (S1 Table). Writ-
ten informed consent was received from these subjects prior to enrollment and/or from their
parents or guardians for participants below 18 years of age. All patients in the collection were
screened for clinical signs and specifically for neurological and psychiatric disturbances. Sam-
ples from patients testing positive for microscopic presence of malaria (blood smear), filariasis
(blood examination by capillary tube centrifugation), schistosomiasis (when blood was
detected in urine), as well as by retrospective testing of stored samples for HIV and syphilis,
were excluded. All clinical samples that remained after the above clinical diagnostic procedures
were aliquoted and stored in liquid nitrogen before being transported on dry ice to the Insti-
tute of Tropical Neurology at Limoges University. The anonymized samples were archived
and stored at -70˚C and at no time was there a break in the cold-chain until the aliquoted sam-
ples were used for the LAMP assay for this study. Because it is not ethical to perform a lumbar
puncture on a healthy person, we used negative control human CSF obtained as discarded de-
identified clinical samples from The Johns Hopkins Hospital Microbiology laboratory that
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were obtained from patients with neurological manifestations with approval of the Johns Hop-
kins Medicine Institutional Review Board (IRB).
Screening for trypanosomes and HAT staging
Gambiense HAT was confirmed by a positive card agglutination test for trypanosomiasis
(CATT) and with trypanosomes microscopically identified in blood and posterior cervical
lymph nodes if latter were enlarged, and on CSF smears based on WHO guidelines adapted
for populations where the prevalence of the HAT is high- (> 1%) areas [12]. Based on the
prevalence of HAT in the area our cohort was obtained, our decision pathways were based on
a published algorithm (Fig 1 in ref [26]) modified with a focus on having a real "stage-1"
group. We considered all patients with presence of trypanosomes in blood or lymph and with
less than 5 white blood cells (WBC)/μL), no trypanosomes in CSF and no neurological signs as
stage-1. All others at stage-2, so patients with 10 cells without trypanosomes in CSF were con-
sidered stage-2. A positive CATT at�1:16 dilution with documented trypanosomes (either by
microscopy or by mAECT) was our reference standard for confirmed gambiense HAT. Posi-
tive CATT�1:16 without evidence of trypanosomes was considered serologic HAT. Positive
CATT�1:4 but<1:16 without evidence of trypanosomes was considered possible HAT. Nega-
tive CATT (<1:4) was considered not HAT (control). Patients with HAT and CSF with evi-
dence of IgM (nephelometric detection) [27], or trypanosomes (microscopic detection), or
increased CSF white cell blood count (> 5 WBC/μL), or relapse after stage-1 HAT treatment,
were classified as stage-2 HAT. Patients presenting with HAT without IgM or trypanosomes
in the CSF and with CSF cell counts�5 WBC/μL who had not relapsed after stage-1 treatment
were also considered stage-1 HAT. The presence or absence of trypanosomes (by microscopy
or mAECT) dictated whether stage-1 and stage-2 HAT cases were confirmed or serologic,
respectively. Overall, the final cohort consisted of de-identified archived CSFs from 150 HAT
patients—includes 95 adults; 21 patients between the ages of 12 to 17; and 34 patients <12
years of age—clinically defined as stage-1 (73 samples) or stage-2 (77 samples). Negative con-
trol samples were available from 100 patients.
RIME and TBG1 LAMP primer sets
Two LAMP primer sets targeting the pan-T. brucei—500 copy—repetitive insertion mobile
element (RIME) of subgenus Trypanozoon (GenBank Accession No. K01801) (RIME LAMP)
and the—200 copy—T. b. gambiense 5.8S rRNA-internal transcribed spacer 2 (5.8S-ITS2) gene
(GenBank Accession No. AF306777) (TBG1 LAMP) were used (S2 Table). The analytical
specificity for trypanosome DNA and sensitivity (equivalent to 0.01 parasite or less) for RIME
and TBG1 LAMP are well documented [20, 22, 23, 28, 29]. All LAMP primers (Forward and
Backward Primers F3 and B3; Forward and Backward Inner Primers FIP and BIP; and For-
ward and Backward Loop Primers LF and LB) were synthesized and HPLC-purified by Inte-
grated DNA Technologies (IDT).
LAMP reaction assays
A 10% (w/v) Triton X-100 stock solution was made by adding 1 g Triton X-100 to a final vol-
ume of 10 mL DNase/RNase free water (Qiagen). The clinical CSF samples were adjusted to
contain 1/20 volume of 10% Triton X-100 (final concentration 0.5% Triton), or 1/20 volume
deionized water (untreated sham CSF) [22]. The CSFs were assayed immediately or after a 60
min incubation at ambient temperature to allow for complete detergent lysis prior to LAMP as
we previously described [22]. All LAMP reactions using commercially available kits (Eiken
Chemical Co, Japan) were previously optimized for reagent concentration, reaction time and
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temperature in real-time in a Loopamp real-time turbidimeter LA320C (Teramecs, Tokyo,
Japan) as previously described [17, 22, 29, 30]. Briefly, the reaction contained 12.5 μL of 2x
LAMP buffer (40 mM Tris-HCl [pH 8.8], 20 mM KCl, 16 mM MgSO4, 20 mM [NH4]2SO4,
0.2% Tween 20, 1.6 M Betaine, 2.8 mM of each deoxyribonucleotide triphosphate), 1.0 μL
primer mix (5 pmol each of F3 and B3, 40 pmol each of FIP and BIP) or 1.3 μL when LF and
LB (20 pmol each) were included, 1 μL (8 units) Bst DNA polymerase (New England Biolabs,
Tokyo, Japan) and 1 μL of human CSF. Final volumes were adjusted to 25 μL with water.
LAMP reactions monitored for 60 min by measuring turbidity in real-time as previously
described [22] were conducted in duplicate and at optimal reaction temperatures, 62˚C for
RIME LAMP and 63˚C for TBG1 LAMP, prior to termination at 80˚C for 5 min. We consid-
ered precipitation occurring after a reaction time of 60 minutes to be nonspecific artifacts.
For end-point analysis (S1 Fig) the amplified products were analyzed using the E-Gel high
throughput DNA electrophoresis system with ethidium bromide or SYBR green incorporated
into the gels (Invitrogen), or after addition of hydroxy naphthol blue (HNB) to monitor the
sample color change from violet to sky blue, a readout unaffected by detergent, has been inter-
preted by independent observers as the easiest to see [23]. As with any DNA amplification
method, standard precautions for avoiding template contamination [31] also apply for LAMP-
based assays. Thus, the reactions were assayed in 4 blocks with each block containing 8 sam-
ples with 2 no template controls for every 6 samples assayed. A false positive response from
any no template or non-HAT CSF control negated the entire 32-reaction run and the samples
were re-assayed.
Statistical analysis
Statistical significance between data sets obtained with RIME versus TBG1 LAMP was deter-
mined using the Cohen’s kappa coefficient (Vassar Stats; http://vassarstats.net/kappa.html) as
a measure of agreement between Triton X-100 pretreated patient CSF samples that were posi-
tive or negative for trypanosomes. For reference, the following Kappa coefficients and levels of
agreement are as follows: 0.80 to 1.00 = Very good agreement, 0.60 to 0.80 = Good agreement,
0.40–0.60 = Moderate agreement, 0.20–0.40 = Fair agreement, while values<0.20 = Poor
agreement. Additionally, we applied the χ2 test and Fisher’s exact probability test to the 2x2
contingency table generated comparing the two approaches (Vassar Stats; http://vassarstats.
net/tab2x2.html).
Results
Using pan-T. brucei RIME LAMP as our ‘gold standard’ LAMP assay, conventional WHO
staging concepts predicted that a significant number of the stage-2 CSF samples would be
LAMP positive, while the stage-1 CSFs would yield predominantly negative results. To estab-
lish baseline clinical control values, RIME and TBG1 LAMP were performed on at least 100
negative control CSF samples obtained from the Johns Hopkins Hospital (Baltimore, MD
USA). All control CSF samples were found to be RIME- and TBG1 LAMP-negative whether
or not they were pre-incubated for 1 h with detergent prior to assay to allow for optimal sam-
ple lysis [22]. We then tested the archived CSFs from 150 HAT patients—includes adults and
children the between the ages of 3 to 17 years)—clinically defined as stage-1 (73 samples) or
stage-2 (77 samples of which 4 were microscopically parasite positive) (S1 Table). Overall,
under sham conditions using only 1 μL sample and pan-T. brucei RIME LAMP, we found that
1/73 (1.4%) of the stage-1 samples tested positive possibly due to the presence of circulating
free DNA (cfDNA), as the patient was previously treated for HAT (S1B Table; see below) and
2/77 (2.6%) of the stage-2 HAT CSF samples tested were parasite DNA-positive by pan-T.
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brucei RIME LAMP. We have shown that release of parasite DNA by 0.5% Triton required
between 30 and 60 min incubation [22]. While the percentage of trypanosome DNA-positive
CSFs by RIME LAMP conducted immediately after Triton X-100 addition increased 2-fold,
LAMP conducted 60 min after detergent addition revealed that 21 out of 77 (27.3%) stage-2
CSFs tested were parasite DNA-positive (Table 1A). In patients with HAT, especially with T.
b. rhodesiense, it is more difficult to detect trypanosomes in the CSF compared with the blood
where the parasitaemia is generally high [9] though much less so in T. b. gambiense. Remark-
ably, even under our stringent assay conditions whereby only 1 μL of CSF was directly assayed,
RIME LAMP with detergent did identify 2 (1 adult (ID 8) and 1 pediatric <12 years of age (ID
107); S1 Table) of the 4 patient CSFs in which trypanosomes were identified microscopically.
Somewhat unexpected was the dramatic 1.4% (2/73) to 42.5% (31/73) increase in the number
of parasite DNA-positive CSFs for stage-1 samples (Table 1A).
It has been suggested that molecular tests (PCR) may not be suitable for post-treatment fol-
low-up of HAT cure because of persistence of trypanosome cfDNA that may lower test speci-
ficity [32–34]. Released into the bloodstream as a result of cell death, necrosis, or by release by
viable cells, cfDNA has been found in many disease conditions [35]. In our cohort, 22 samples
(9 stage-1 and 13 stage-2) were from patients that had previously been treated (with some try-
panocide) for HAT prior to sample collection (S1B Table). While 8 out of 9 stage-1 and 5 out
of 13 stage-2 Triton-pretreated samples were RIME LAMP positive, one stage-1 sample, ID2,
and two stage-2 samples, ID1 and ID12, were strongly LAMP positive under sham condition.
In fact, this was the only sham sample in the entire 150 sample cohort positive for trypanosome
DNA (Compare S1A Table to S1B Table).
A re-analysis of the 128 samples from HAT patients who never received any trypanocide
prior to collection (S1A Table), also showed that while none of the stage-1 samples were
LAMP-positive, 3.1% of the stage-2 HAT CSF samples tested were parasite DNA-positive by
RIME LAMP, a value predicted provided that the samples on average had 1 parasite / 20 μL
Table 1. Fraction of CSF samples LAMP positive for trypanosome DNA.
A) FOR ALL ADULT AND PEDIATRIC PATIENTS
RIME LAMP TBG1 LAMP
Preincubation Preincubation
HAT stage Sham
60 min
Tx100
60 min
Tx100
0 min
Sham
60 min
Tx100
60 min
1 1/73
(1.4%)
31/73
(42.5%)
2/73
(2.7%)
1/72
(1.4%)
29/73
(39.7%)
2 2/77
(2.6%)
21/77
(27.3%)
4/77
(5.2%)
1/76
(0%)
19/77
(24.7%)
1+2 3/150
(2.0%)
52/150
(34.7%)
6/150
(4.0%)
2/149
(1.4%)
47/150
(31.3%)
B) FOR PATIENTS WITH NO PRIOR TRYPANOCIDE TREATMENT
RIME LAMP TBG1 LAMP
Incubation Incubation
HAT stage Sham
60 min
Tx100
60 min
Tx100
0 min
Sham
60 min
Tx100
60 min
1 0/64
(0%)
23/64
(35.9%)
1/64
(1.6%)
1/64
(1.6%)
20/64
(46.9%)
2 2/64
(3.1%)
16/64
(25.0%)
4/64
(6.3%)
1/64
(1.3%)
17/64
(26.6%)
1+2 2/128
(1.6%)
44/128
(34.4%)
5/128
(3.9%)
2/128
(1.6%)
37/128
(28.9%)
https://doi.org/10.1371/journal.pntd.0007631.t001
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sample assayed: i.e. 1/20 x 64 = 3.2%. RIME LAMP conducted on these Triton pretreated CSF
samples showed a 25% (16/64) increase in the number stage-2 CSFs as well as a 35.9% (23/65)
increase in the number of parasite DNA positive stage-1 samples (Table 1B). These findings
were confirmed by repeating the experiments in the absence or presence of Triton using TBG1
LAMP targeting the T. b. gambiense specific 5.8S-ITS2 gene (S1 Table and Table 1 and Fig 1).
When properly executed, detergent-enhanced LAMP is able to detect very low parasite
numbers, but the assay’s sensitivity is a potential drawback because of risk for amplicon con-
tamination. Thus, we used the Cohen’s kappa test to compare the LAMP data from two unre-
lated trypanosome gene targets. Based on data derived from the entire cohort, Cohen’s kappa
test identified a high level of agreement between RIME and TBG1 LAMP in samples that had
been pre-incubated with Triton X-100 prior to assay (the most sensitive condition) when test-
ing CSFs, thus indicating that the results are not due to amplicon contamination (Table 2).
Kappa coefficients for RIME versus TBG1 LAMP of 0.92 (95%CI: 0.82–1.00) for stage-1 and
0.90 (95%CI: 0.80–1.00) for stage-2 reflect a high level of agreement between the data set, data
confirmed in χ2 tests (p<0.001) and Fisher’s exact probability test (p = 4.7e-13). Inclusion of
the 100 negative control CSFs strengthens the level of agreement: 0.94 (95%CI: 0.87–1.00) for
stage-1 and 0.92 (95%CI: 0.83–1.00) for stage-2. Re-analysis of Kappa after removing the 22
samples from patients previously treated with trypanocide (data from S1B Table only) did not
significantly change the kappa coefficients for RIME versus TBG1 LAMP for stage-1 and for
stage-2 HAT; 0.90 (95%CI: 0.78–1.00) for stage-1, 0.88 (95%CI: 0.75–1.00) for stage-2, and
0.89 (95%CI: 0.81–0.98) for all stages.
Discussion
This paper is a continuation of a published study [22] that demonstrated the power of deter-
gent-enhanced LAMP assay to detect low numbers of live African trypanosomes in human
CSF or blood experimentally spiked with the parasites. The findings led us to predict that
detergent-enhanced LAMP will provide a simple, sensitive, and specific assay platform for
detection of parasites in clinical samples for T. b. gambiense HAT where low parasitemias are
to be expected. Taking into consideration that the concentration of T. b. gambiense in 1 mL of
HAT patient blood is often < 100 parasites (i.e. < 2 parasites/20 μl) [3], for proof-of-concept a
minimal parasite detection threshold of�50 parasites/mL (or 1 parasite/20 μL sample) was
thus established. Therefore, while one would have to test up to 20 individual LAMP assays
based on a 1 uL test sample volume to be certain of detecting the DNA from the single intact
parasite in the sample, detergent-enhanced RIME or TbG1 LAMP would only require a single
determination. However, while any positive response would indicate that the sample had at
least 50 parasites/mL, a negative response does not necessarily mean that the sample was truly
negative, just below the 50 parasite/mL detection limit set by the limit of the sample size tested.
While based on a single clinical cohort our findings are intriguing in that the data provide
evidence for detection of genomic T. b. gambiense DNA in the CSF independent of HAT stage
and patient age. The data also provide suggestive clinical evidence for early CNS entry, sup-
ported by clues drawn from the T. b. brucei and T. b. rhodesiense literature [36–38]. In a
murine brain invasion model, intravital microscopy revealed that African trypanosomes caus-
ing acute (i.e. T. b, rhodesiense IL1852 and T. b. brucei 90–13) and chronic (i.e. T. b. brucei
GVR/35) disease directly invade the cerebral cortex parenchyma within hours after high dose
(106 parasites) retroorbital administration followed by inflammatory cell recruitment soon
thereafter without associated neurological signs [36]. When given a low dose intraperitoneal
inoculation of T. b. brucei GVR/35 (2×104 parasites), brain imaging documented parasites in
the meninges [37] and cerebellum days earlier than was predicted from pharmacological
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studies alone [39, 40]. with CNS impairment occurring prior to the onset of established stage-2
disease [41]. Neurological signs in rats can also occur before trypanosomes enter the neuropil
and parasite/lymphocyte invasion of brain parenchyma [42], which appears to be in line with a
clinical report that the early neurological features in some rhodesiense HAT patients with
stage-1 HAT can be detected prior to the onset of established stage-2 disease [43]. Finally, test-
ing 5 different algorithms used by Me´decins Sans Frontie‘res HAT programmes Checchi et al
[26] found that while stage 2 classification was highly accurate, about one third of stage 1 cases
Fig 1. Percentage (%) of CSF samples positive for trypanosome DNA by RIME and TBG1 LAMP based on Table 1 data.
https://doi.org/10.1371/journal.pntd.0007631.g001
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were misclassified as stage 2. Thus, these [26] and current WHO criteria leave open the need
to consider other approaches that go beyond the prevailing notion that the transition from
acute to CNS stage disease entails crossing brain barriers to enter the CNS to initiate inflam-
mation that define clinical staging for CNS [41].
The development of simple non-invasive detergent-enhanced LAMP assay platforms for
POC detection of trypanosomes in human saliva and skin with sensitivities equivalent or supe-
rior to current invasive methods, is an important POC diagnostic goal. Lejon et al. first showed
that detection of T. b. gambiense antigens in a non-invasive saliva-based HAT test format was
theoretically possible [44, 45]. A 180-day study in non-human primates comparing LAMP and
PCR targeting the single copy TgsGP gene, found TgsGP LAMP a more sensitive assay format
for detecting T. b. gambiense DNA in several biofluids including serum and saliva [46]. Up to
77 days post infection (dpi) TgsGP LAMP recorded 100% detection in the saliva samples [46].
While LAMP recorded 33% detection in the serum 180 dpi, TgsGP LAMP failed to detect try-
panosomes in saliva after 140 days. Replacing TgsGP-LAMP with detergent enhanced RIME--
LAMP or TBG1 LAMP (this paper and Ref [22]) would in theory yield a 2-log more sensitive
diagnostic.
The same concepts could also be applied for detection of human skin [47, 48] and subcuta-
neous adipose tissue [49–51] dwelling trypanosomes in HAT patients [47, 48]. Capewell et al.
[47] reported that about 0.5% of more than 1000 skin biopsies collected for a river blindness
study in the Democratic Republic of the Congo had morphologically identified skin-dwelling
T. b. gambiense in extravascular and subcutaneous adipose tissue a finding that could explain
the persistence of HAT in some areas despite eradication efforts [47]. The skin would provide
a large reservoir for the parasites; a consideration for identifying clinically seropositive but
aparasitemic individuals. One caveat is that while the trypanosomes appear to infect patches of
the skin, parasites in other skin areas may be harder to find. We predict that DNA released
from even a single parasite solubilized by detergent will be sufficient for LAMP amplification.
Overall, the skin is another theoretical assay site where non-invasive detergent enhanced
LAMP could have a potential diagnostic impact.
Conclusion
Overall, the evidence support the idea that current WHO criteria need to go beyond the pre-
vailing notion that the transition from acute to CNS stage disease entails crossing brain barri-
ers to enter the CNS to initiate inflammation that define clinical staging for CNS [41].
Whether detection of trypanosome genomic DNA by detergent-enhanced LAMP in the CSF
Table 2. Cohen’s kappa test comparing detergent-enhanced RIME versus TBG1 LAMP.
FOR ALL STAGE-1 AND STAGE-2 HAT CSFS
HAT Stage # CSF Samples kappa Coefficient 95% Confidence Interval
1 73 0.92 0.82–1.00
2 77 0.90 0.80–1.00
1+2 150 0.91 0.84–1.00
FOR ALL STAGE-1 AND STAGE-2 HAT CSFS INCLUDING NON-HAT CSF CONTROLS
HAT Stage # CSF Samples kappa Coefficient 95% Confidence Interval
1 73 0.94 0.87–1.00
2 77 0.92 0.83–1.00
1+2 250 0.93 0.87–1.00
�After 60 min preincubation with Triton X-100 prior to LAMP assay
https://doi.org/10.1371/journal.pntd.0007631.t002
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independent of HAT stage provides supportive clinical evidence for early CNS entry, reflects
parasite contamination of CSF with infected blood during lumbar puncture, and/or other sce-
narios, identify critical knowledge gaps for future studies. Controlled laboratory and field vali-
dation of detergent LAMP [22] or the adaptation of more recent ultrasensitive LAMP assays
based on DNA-protein chimeras called LAMPoles for detection of non-nucleic based targets
[52] that include HAT staging biomarker molecules [53, 54] that take into account saliva, skin
and subcutaneous fat-dwelling trypanosomes may help facilitate development of better algo-
rithms for HAT diagnosis and monitoring. Further, the detection of parasite DNA regardless
of sample source by detergent LAMP may help provide for very early T. b. gambiense HAT
diagnosis regardless of staging. The use of these LAMP-based platforms as epidemiologic tools
for the determination human African trypanosome prevalence in areas where chronically low
parasitemias are present or in areas where there are high numbers of asymptomatic (carriers)
patients should also be considered.
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